Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases.
Research
Innovation
Discover how ÐǺ£ÆåÅÆ makes a positive impact for patients, communities, employees and the environment
Corporate and financial resources for ÐǺ£ÆåÅÆ investors, potential shareholders and analysts
Resources
Financials
Stock Information
Governance
NationalityAmerican
Mr. Bailey joined ÐǺ£ÆåÅÆ in 2020 and became Executive Vice President and Chief Commercial Officer effective August 19, 2024. Mr. Bailey leads ÐǺ£ÆåÅÆ’s commercial organization globally and is responsible for driving growth across the company’s portfolio and delivering its antibody-based medicines to patients.
In his prior role as Senior Vice President and General Manager of the United States, Mr. Bailey established the company’s commercial organization in the US and led the launches of ÐǺ£ÆåÅÆ’s first two marketed medicines.
With more than 25 years in the healthcare industry, Mr. Bailey has extensive experience in strategic and operational commercial leadership roles across specialty biopharma, oncology, immunology, and other serious diseases in the US and around the world.
He holds a Bachelor of Science in Business Administration from Clemson University.